Crossref
289 Therapeutic Potential of MY004, an IRAK4 Inhibitor, in Psoriasis: Preclinical Activity and Molecular Mechanism
Journal of Investigative Dermatology · 2025-11 · 145 (11) · e77
DOI: 10.1016/j.jid.2025.09.293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025-11. Verfasst von Ying He und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
He, Y., Xu, K., Xiong, Y., & Li, W. (2025). 289 Therapeutic Potential of MY004, an IRAK4 Inhibitor, in Psoriasis: Preclinical Activity and Molecular Mechanism. Journal of Investigative Dermatology, 145(11), e77. https://doi.org/10.1016/j.jid.2025.09.293
Vancouver
He Y, Xu K, Xiong Y, Li W. 289 Therapeutic Potential of MY004, an IRAK4 Inhibitor, in Psoriasis: Preclinical Activity and Molecular Mechanism. Journal of Investigative Dermatology. 2025;145(11):e77. doi:10.1016/j.jid.2025.09.293
BibTeX
@article{He2025,
author = {He, Ying and Xu, Keyu and Xiong, Yufei and Li, Wei},
title = {289 Therapeutic Potential of MY004, an IRAK4 Inhibitor, in Psoriasis: Preclinical Activity and Molecular Mechanism},
journal = {Journal of Investigative Dermatology},
year = {2025},
volume = {145},
number = {11},
pages = {e77},
doi = {10.1016/j.jid.2025.09.293}
}
EUVIMED